Deutsche Bank Maintains Buy Rating On MAPP After Unexpected Q1 Profit

In a recent report, Deutsche Bank maintained a buy rating on MAP Pharmaceuticals MAPP and reported on the unexpected profit resulting in a $0.56 EPS versus Deutsche Bank's previous estimate of $0.36. In the report, Deutsche Bank said, "Based upon a significant unmet need among migraine sufferers and positive clinical results to date, we continue to believe that Levadex is an attractive late stage asset that could potentially generate peak WW sales of $400M+, if approved." MAPP closed yesterday at $15.11.